FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Related Keywords

Japan ,Westchester ,New York ,United States ,West Palm Beach ,Florida ,Illinois ,Memorial Sloan Kettering Cancer Center ,Chicago ,Boston ,Massachusetts ,Japanese ,American ,America ,Racheln Grisham ,Asia Pacific ,Davidm Omalley ,Department Of Obstetrics ,Ohio State University College Of Medicine ,Florida Cancer Specialists Research Institute ,Drug Development Summit ,Gynecologic Oncology Group Study ,Onclive News Network Program ,Ohio State University Comprehensive Cancer Center ,American Society Of Clinical Oncology Annual Meeting ,Division Of Gynecologic Oncology ,Combination Component ,Ovarian Cancer ,Florida Cancer Specialists ,Research Institute ,Ohio State University College ,Gynecologic Oncology ,Onclive News Network ,Targeted Drug Development Summit ,Clinical Oncology Annual Meeting ,Gynecologic Oncology Group ,Gynecologic Oncology Annual Meeting ,Verastem Oncology ,North America ,Integrative Oncology ,Bradleyj Monk ,D ,Pacs ,Iacog ,Fak Inhibition ,Florida Cancer Specialists Amp Research Institute ,The Ohio State University Comprehensive Cancer Center James ,Davidmo Malley ,Defatinib ,Ifebemtinib ,